CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
Scientists at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and the Institute for Research in ...
A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...
In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results